Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC , Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA will raise prices in the US on over 350 unique drugs in early January.
The increases are in preparation for the Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices for some drugs starting in 2026.
The pharmaceutical industry is also dealing with inflation and supply chain constraints that increased manufacturing costs.
The price hikes are based on list prices, which do not account for other discounts or rebates to pharmacy benefit managers.
According to data released by 46brooklyn, a drug pricing non-profit affiliated with 3 Axis, drugmakers increased prices on more than 1,400 pharmaceuticals in 2022. Since 2015, there have been the most rises.
According to Antonio Ciaccia, president of 3 Axis, drugmakers have concentrated on releasing their medications at higher prices due to the concentration on annual price hikes.
More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices.
Pfizer has so far disclosed the biggest price hikes, with 89 different prescription names seeing a rise in price in addition to an extra 10 drug brands at its Hospira division.
Then came GSK, which has already announced hikes for 26 different medications, including nearly a 7% rise for its well-known shingles vaccine Shingrix.
